Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Combination of ZEN-3694 with CDK4/6 inhibitors reverses resistance in ER-positive breast cancer
https://www.zenithepigenetics.com/upload/media_element/120/01/aacr-2020-1750-abstract-2346.pdf
https://www.abstractsonline.com/pp8/#!/9045/presentation/1852